PROMEX

Main information

  • Trade name:
  • PROMEX 25 TABLETS TRANQUILLISER
  • Pharmaceutical form:
  • ORAL TABLET
  • Units in package:
  • 150Tab,500Tab
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug
  • Manufactured by:
  • APEX LABORATORIES

Documents

Localization

  • Available in:
  • PROMEX 25 TABLETS TRANQUILLISER
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • CAT | DOG | BITCH | CASTRATE | CAT - QUEEN | CAT - TOM | KITTEN | PUPPY
  • Therapeutic area:
  • sedative,tranquilser
  • Therapeutic indications:
  • PRE-ANAESTHETIC | TRANQUILLISER | ANAESTHETIC PREMEDICANT | CALMING AGENT | SEDATIVE
  • Product summary:
  • Tranquilliser for sedation and/or pre-anaesthetic medication of dogs and cats.

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered but not available
  • Authorization number:
  • 35682/0502
  • Authorization date:
  • 15-05-2002
  • Last update:
  • 15-06-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

Apex Laboratories Pty Ltd

Promex 25 Tranquilliser Tablets

Specification No: LB-PROMEX25/A

Supersedes:

PRESCRIPTION

ANIMAL

REMEDY

KEEP

OUT

OF

REACH

OF

CHILDREN

FOR

ANIMAL

TREATMENT

ONLY

PROMEX

25

TABLETS

TRANQUILLISER

EACH

TABLET

CONTAINS:

ACEPROMAZINE

MALEATE

EQUIV

ALENT

25mg

ACEPROMAZINE

BASE

TABLET

INDICATIONS:

TRANQUILLISER

SEDATION

AND/OR

PRE-ANAESTHETIC

MEDICATION OF DOGS AND

CATS.

(150

Tablets/500

Tablets)

F:\WOrd\REGO\LABEL~4LAB.DOC

Page 1 of

29 October 2001

Label: Self adhesive

DIRECTIONS

FOR

USE:

TO 1

TABLETS/12.5KG

BODYWEIGHT.

APEX

LABORATORIES

PTY

LTD

Chivers Rd Somersby

2250

Australia

Dispose of

empty

container

wrapping

paper

putting

garbage.

Store Below 25°C (Air Conditioning)

NRA:

35682/0SD'L

Batch:

Expiry:

MADE IN

AUSTRALIA

FROM

IMPORTED

AND LOCAL

INGREDIENTS

~::~~:E~;~k;~~

Date:

.J§":

..

~.J-:?~.·

signatureA:

' ....

V

13-11-2018

Oscor Inc. Issues Recall Product Expansion of TB – Temporary Bipolar Pacing Lead (Unshrouded 2 mm Pins Models)

Oscor Inc. Issues Recall Product Expansion of TB – Temporary Bipolar Pacing Lead (Unshrouded 2 mm Pins Models)

On September 26, 2018 Oscor notified customers of a recall for certain lots (Recall No. 1035166- 09/07/2018-01-R) of TB Unshrouded Bipolar Pacing Leads. As part of the recall correction activities, Oscor is retrieving any remaining inventory out in the field. The recall scope is being expanded to include expired inventory for devices distributed between December 21, 2011 to May 17, 2018. The recall expansion is to ensure proper disposition of expired units. The FDA has been notified and is aware Oscor In...

FDA - U.S. Food and Drug Administration

9-11-2018

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Published on: Wed, 07 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP Panel) assessed the safety of the additive Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials. It is a family of mixtures combining the four lanthanides lanthanum (La), europium (Eu), gadolinium (Gd) and/or terbium (Tb) in different proportions as their 1,4‐benzene dicarboxylate complexes, used as a taggant in plastics for authentication and ...

Europe - EFSA - European Food Safety Authority Publications

27-9-2018

Oscor Inc. Issues Recall of TB – Temporary Bipolar Pacing Lead (Unshrouded 2 mm Pins Models)

Oscor Inc. Issues Recall of TB – Temporary Bipolar Pacing Lead (Unshrouded 2 mm Pins Models)

During the use of some TB - Temporary Bipolar Pacing Leads, featuring the 2mm unshrouded connectors, the connector cap housing (see Picture 1, No. 2 Pin Cap and Cover) may slide and potentially expose the connection wire. In some instances, this may cause the wire to be more susceptible to loss of connectivity or breakage during movement of the cables causing interruption of the pacing system. The analysis of the returned devices attributed the failure to a design change of the cap housing of the pins. ...

FDA - U.S. Food and Drug Administration

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Pixuvri,pixantrone (dimaleate), decision type: , therapeutic area: , PIP number: P/0227/2018

Opinion/decision on a Paediatric investigation plan (PIP): Pixuvri,pixantrone (dimaleate), decision type: , therapeutic area: , PIP number: P/0227/2018

Opinion/decision on a Paediatric investigation plan (PIP): Pixuvri,pixantrone (dimaleate), decision type: , therapeutic area: , PIP number: P/0227/2018

Europe - EMA - European Medicines Agency

23-11-2018

.@US_FDA issues Class I Medical Device Recall, the most serious type of   recall: Oscor Recalls TB Temporary Bipolar Pacing Leads Due to  Connector Separation Causing Potential for Loss of Pacing. Find out  more:  https://go.usa.gov/xPHxF  #FDA #MedicalDe

.@US_FDA issues Class I Medical Device Recall, the most serious type of recall: Oscor Recalls TB Temporary Bipolar Pacing Leads Due to Connector Separation Causing Potential for Loss of Pacing. Find out more: https://go.usa.gov/xPHxF  #FDA #MedicalDe

. @US_FDA issues Class I Medical Device Recall, the most serious type of recall: Oscor Recalls TB Temporary Bipolar Pacing Leads Due to Connector Separation Causing Potential for Loss of Pacing. Find out more: https://go.usa.gov/xPHxF  #FDA #MedicalDevice pic.twitter.com/negJ6HU4x2

FDA - U.S. Food and Drug Administration

30-7-2018

Apoquel (Zoetis Belgium S.A.)

Apoquel (Zoetis Belgium S.A.)

Apoquel (Active substance: Oclacitinib maleate) - Centralised - Renewal - Commission Decision (2018)5153 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2688/R/13

Europe -DG Health and Food Safety